November 21st 2024
Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.
Surgeons More Selective With Surgeries in Late-Stage Cancer Patients
May 13th 2015A study published in the Journal of Surgical Research has found that surgeons are focusing on life-enhancing procedures for late-stage cancer patients. In their follow-up on 22,000 late-stage cancer patients in the United States between 2006 and 2010, while the use of surgeries declined only slightly, doctors became more likely to restrict surgery to healthier patients.
Read More
New HPV Vaccine Can Protect Against 80% of Cervical Cancers, Study Estimates
May 12th 2015The study, published in the Journal of the National Cancer Institute found that in addition to protecting against 80% of cervical cancers, the new Gardasil-9 has the potential to protect against nearly 19,000 other cancers diagnosed in the United States.
Read More
Parent Belief Determines HPV Vaccination Rates in Young Girls, Study Finds
May 11th 2015Based on their analysis of a mail-in questionnaire, researchers in Canada found that parents who had their daughters vaccinated differed from those who did not do so in perceived susceptibility to the disease, benefits and barriers of the vaccine, and cues to action.
Read More
Breast, Cervical, Colorectal Cancer Screenings Below Target, CDC Reports
May 8th 2015Overall, regular breast, cervical, and colorectal cancer screening was below target in 2013, according to a new report from the CDC. In fact, researchers found overall screening in these 3 areas showed no improvements from 2010 to 2013.
Read More
Study Says Second Opinions Matter in Breast Cancer Pathology
May 8th 2015The Roswell Park pathology team reviewed 500 breast core biopsy cases provided by referring institutions in a single calendar year and found that 8% of the cases had a major discordance and 13% had a minor discordance, especially with respect to interpreting biomarkers that determine prognosis and therapeutic options.
Read More
Study Points to Improved PFS in Prostate Cancer Patients on Statin Therapy
May 7th 2015The study conducted by researchers at Dana-Farber Cancer Institute, and published in JAMA Oncology, found a siginificant increase in progression-free survival in men who initiated statin therapy along with androgen deprivation for their prostate cancer.
Read More
Surgery for Terminally Ill Cancer Patients Remains Prevalent
May 6th 2015Although 30-day morbidity and mortality all declined incrementally for terminally ill cancer patients undergoing surgical intervention from 2006-2010, the number of surgeries remains high, according to a study from University of California, Davis Health System.
Read More
Pharma Seeks Early Price Discussions With Payers
May 5th 2015The pharmaceutical industry has learnt its lesson from the pushback that Gilead faced over the price of its hepatitis C drug, Sovaldi. The lack of a price discussion prior to the introduction of the regimen washed-out the excitement over a "cure" for the disease.
Read More
Challenges With Including PROs in Oncology Product Labels
May 1st 2015The debate over including patient reported outcomes on oncology drug labels continues. The FDA expects well-defined and validated measurement tools and the patient community wants patient experiences to find their way to the label.
Read More
Express Scripts Eyeing Pricey Cancer Drugs Next
May 1st 2015Pharmacy benefit manager Express Scripts Holding Co, which has aggressively negotiated lower costs of new hepatitis C drugs, on Wednesday said a new "focus area" will be subduing costs of a growing wave of pricey biotech cancer drugs.
Read More
Independent Committee Recommends T-Vec for Approval Despite FDA Staff Concerns
April 30th 2015Amgen might be the latest entrant in the immunotherapy realm if the FDA heeds the advice of an independent advisory panel, recommending Amgen's anticancer viral therapy, T-Vec, for melanoma treatment.
Read More
Nivolumab May Soon Be Approved as First-Line in Advanced Melanoma
April 30th 2015A press release by Bristol-Myers Squibb announced their filing of a supplemental Biologics License Application for Opdivo (nivolumab) in the treatment of previously untreated individuals with advanced melanoma.
Read More
European Consortium Aims to Validate Blood-Based Cancer Biomarkers
April 29th 2015The consortium, called CANCER-ID, is a partnership between 33 organizations across 13 European nations focused on establishing the clinical utility of liquid biopsies in patients with NSCLC and HER2-resistant breast cancer.
Read More